TORONTO, Sept. 7 /PRNewswire-FirstCall/ - The Westaim Corporation will
hold a webcast at 9:00 a.m. EDT on Wednesday September 8, 2004 regarding
NUCRYST Pharmaceuticals' results of its first Phase 2a human clinical trial.
The investigational drug (NPI 32101) is being studied for atopic dermatitis, a
form of eczema, and represents a biological application of nanotechnology.
In addition to standard disclosure over wire services, a news release
will be posted on the Westaim web site. To listen to the call live on the
Internet, please go to www.westaim.com.
Barry M. Heck, President & Chief Executive Officer, The Westaim
Corporation, Scott H. Gillis, President, NUCRYST Pharmaceuticals and Dr. Paul
J. Schechter, Vice President, Drug Development and Regulatory Affairs, Chief
Medical Officer, NUCRYST Pharmaceuticals will participate on the call.
An audio file of the call will be archived and posted on the Westaim web
NUCRYST Pharmaceuticals Corp. (www.nucryst.com) researches and develops
pharmaceutical products based on noble metal nanocrystalline technology.
Potential products are in development for dermatology and severe respiratory
conditions. The company has also profitably commercialized its technology for
wound care with Acticoat(TM) antimicrobial dressings for serious wounds
including life-threatening burns, using NUCRYST's proprietary SILCRYST(TM)
nanocrystalline technology. These products are marketed, sold and distributed
by Smith & Nephew, the world's leading advanced wound care company.
In addition to NUCRYST Pharmaceuticals, The Westaim Corporation's
technology investments include iFire Technology, which has developed a
revolutionary low-cost flat panel display. Westaim's common shares are listed
on NASDAQ under the symbol WEDX and on The Toronto Stock Exchange under the
trading symbol WED.
SOURCE Westaim Corporation